TOI ONCOLOGY INSTITUTE INC (THE)

The Oncology Institute Executives to Speak at Key Industry Conferences in Q4

The Oncology Institute Executives to Speak at Key Industry Conferences in Q4

Publicly traded company leaders will share perspectives on the future of value-based oncology care

CERRITOS, Calif., Oct. 17, 2022 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc (NASDAQ: TOI), one of the largest value-based oncology groups in the United States, announced its executives' participation in upcoming key industry conferences. TOI executive visibility is increasing this year as the company experiences growth in new markets driven by market demand and investor interest in its proven value-based model.

TOI’s CEO Brad Hively welcomed the opportunities, commenting, "We look forward to exchanging ideas about how to advance oncology. Now more than ever, the healthcare industry is positioned to provide cutting-edge oncology care while reducing inefficiencies. I look forward to these opportunities for collaboration."

Company executives will be speaking at the Association for Value-Based Cancer Care conference held from October 19-21 in New York, New York. Chief Executive Officer Brad Hively will participate in the session Wall Street and Capital Markets and the Impact on Cancer Care to be held on October 19. Chief Operating Officer Dr. Matt Miller will participate in Lessons Learned from OCM That Should be Incorporated into EOM and Future Cancer Care Models to be held on October 20 and Practice Transformation Through Value-Based Analytics on October 21. Chief Medical Officer Dr. Yale Podnos will participate in The Impact Pathways Have on Outcomes and Value to be held on October 21.

TOI President Dr. Daniel Virnich will speak at the Reuters Oncology at Total Health 2022 Conference in Chicago, Illinois. He will be participating in the session Drug Cost Support and Funding programs on October 20, 2022.

Chief Executive Officer Brad Hively will speak at the America’s Physician Groups Colloquium 2022 Conference in Washington, D.C. He will participate in the session Integrating Value-Based Oncology into Primary Care on November 1, 2022.

TOI executives will speak at the HLTH Conference In Las Vegas, Nevada. Chief Development Officer Debra Richman will participate in the session Innovation and the Ideal Health System on November 14, 2022. Chief Executive Officer Brad Hively will participate in the session Limitless Oncology Care on November 15, 2022.

About The Oncology Institute

Founded in 2007, TOI is advancing oncology by delivering highly specialized, value-based cancer care in the community setting. TOI offers cutting-edge, evidence-based cancer care to a population of approximately 1.7 million patients including clinical trials, transfusions, and other care delivery models traditionally associated with the most advanced care delivery organizations. With 90+ employed clinicians and more than 700 teammates in over 50 clinic locations and growing, TOI is changing oncology for the better. For more information visit

Contacts

Media

The Oncology Institute

Julie Korinke



(562) 735-3226 x 88806

Juan Lezama



(562) 374-8434

Investors

Solebury Strategic Communications

Maria Lycouris



EN
17/10/2022

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on ONCOLOGY INSTITUTE INC (THE)

 PRESS RELEASE

The Oncology Institute Reports Fourth Quarter and Full Year 2025 Finan...

The Oncology Institute Reports Fourth Quarter and Full Year 2025 Financial Results and Guidance for 2026 CERRITOS, Calif., March 12, 2026 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ: TOI) (“TOI” or the “Company”), one of the largest value-based community oncology groups in the United States, today reported financial results for its fourth quarter and year ended December 31, 2025. Recent Operational Highlights Cash flow from operations in Q4 2025 was approximately $3.2 million, due to disciplined working capital management and overall increase in gross profit marginConti...

 PRESS RELEASE

The Oncology Institute Announces Fourth Quarter and Full Year 2025 Ear...

The Oncology Institute Announces Fourth Quarter and Full Year 2025 Earnings Release Date and Conference Call CERRITOS, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (“TOI”) (NASDAQ: TOI)  a pioneer in value-based community oncology care, today announced that the company will release its fourth quarter and full year 2025 financial results on Thursday, March 12, 2026, to be followed by a conference call the same day at 5:00 p.m. (Eastern Time). The conference call can be accessed live over the phone by dialing 1-877-407-0789 or for international callers, 1-201-689-...

 PRESS RELEASE

The Oncology Institute to Participate in Multiple Healthcare Investor ...

The Oncology Institute to Participate in Multiple Healthcare Investor Conferences in March CERRITOS, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ: TOI), a pioneer in value-based community oncology care, today announced that members of its executive leadership team will participate in several investor conferences in March. Details for the conferences are as follows: Jefferies Healthcare Services Innovation & Technology SummitPresentation: Monday, March 9, 2026, from 11:30 a.m. to 12:00 p.m. ETLocation: Miami, FLPresenter: Dr. Daniel Virnich, Chief Execut...

 PRESS RELEASE

The Oncology Institute Appoints Kim Tzoumakas to Board of Directors

The Oncology Institute Appoints Kim Tzoumakas to Board of Directors CERRITOS, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (“TOI”) (NASDAQ: TOI), one of the largest value-based oncology groups in the United States, today announced the appointment of Kim Tzoumakas to its Board of Directors, effective February 23, 2026. Ms. Tzoumakas brings more than two decades of executive leadership experience across oncology, pharmacy services and healthcare operations. Notably, she is Chief Executive Officer for VytlOne National Pharmacy Services, and previously held the CEO r...

 PRESS RELEASE

The Oncology Institute Reaffirms 2025 Guidance and Provides Preliminar...

The Oncology Institute Reaffirms 2025 Guidance and Provides Preliminary 2026 Outlook CERRITOS, Calif., Jan. 12, 2026 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ: TOI) (“TOI” or the “Company”), one of the largest value-based oncology groups in the United States, today reaffirmed 2025 guidance and provided its preliminary 2026 outlook. 2026 Outlook For 2026, TOI anticipates that total revenue will be in the range of $630 million to $650 million, reflecting 28% growth from the midpoint of 2025 and 2026 guidance ranges, and including approximately $150 million of Capitation rev...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch